With three of its highest revenue products going off patent in 2012-14, Lundbeck has embarked on a deal strategy to broaden its product portfolio and increase its geographic reach. Selected licensing deals listed below. Sources: BCIQ: BioCentury Online Intelligence; Lundbeck

Date

Partner

Products

Territories

Deal

Nov. 2011

Otsuka Pharmaceutical Co. Ltd.

Otsuka psychiatry products OPC-34712 and once-monthly depot formulation of aripiprazole; and Lundbeck antipsychotic zicronapine, plus up to two more Lundbeck products to be determined

Worldwide

Cross-licensing deal to co-develop and co-commercialize up to five products. Lundbeck received rights in North America, Latin America, Europe, Australia and undisclosed countries. Otsuka retains rights in Turkey, Egypt and many Asian countries, including Japan.